MiniMed Group, Inc. Q1 FY26 Results

Summary

MiniMed Group, Inc. reported a strong finish to fiscal year 2026, with record annual net sales exceeding $3 billion for the first time, driven by 14.2% reported growth and 8.0% organic growth. The fourth quarter also showed robust performance, with net sales of $837 million, up 15.6% reported and 8.7% organically, fueled by strength in international markets and the adoption of the MiniMedTM 780G system. The company highlighted significant pipeline advancements, including FDA clearances and new product launches, and provided a positive outlook for fiscal year 2027, expecting approximately 10% organic revenue growth and an adjusted EBITDA margin of around 16%.

Key Highlights

1. 1

   MiniMed achieved record annual net sales performance, surpassing $3 billion for the first time, growing 14% as reported and 8% organically.

2. 2

   In the fourth quarter of fiscal year 2026, net sales reached $837 million, representing a 15.6% increase as reported and an 8.7% organic growth year-over-year.

3. 3

   International net sales for the fiscal year 2026 were $2.185 billion, up 20.6% as reported and 11.2% organically.

4. 4

   The company advanced its global pipeline ahead of schedule with FDA clearance for MiniMed FlexTM, CE Mark for Instinct, and the global launch of MiniMed GoTM Smart MDI.

5. 5

   Worldwide net sales for the fiscal year 2026 grew 14.2% as reported to $3.102 billion.

6. 6

   The worldwide CGM Attachment Rate increased to 66% for fiscal year 2026, a significant rise of 700 basis points year-over-year.